The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 52 | — | 20.1x | Near average | |
Growth | 78 | — | 5.6% | Above average | |
Quality | 57 | 992.4% | 7.6% | Near average | |
Safety | 42 | 2.1x | 0.4x | Near average | |
Capital Return | 32 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Alto Neuroscience, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Alto Neuroscience, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ANRO stock has seen a significant improvement in analyst optimism over the past 30 days, with the average price target rising by 12.52% to reach 34.6 dollars. This increase is driven by three new analysts joining the coverage, bringing the total number of analysts to 6, while maintaining positive ratings such as 'Outperform' from Wolfe Research and confirming a 'Buy' rating from H.C. Wainwright, reflecting growing confidence in the company's future prospects despite the absence of current revenue.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.